Research Reports

Key takeaways

Revenue of $1.5B reflects portfolio headwinds, with gross profit of $783.0M and net income of $146.0M.

Gross margin contracted to 53.6% due to unfavorable pricing, product mix, and foreign exchange headwinds.

Operating cash flow of $225M benefited from active cash cycle management, including receivables factoring.

Free cash flow of $188M after capital expenditures of $37M supports liquidity and debt reduction.

Material weaknesses in internal controls over financial reporting remain un-remediated, stemming from former CEO misconduct.

Full analysis

Revenue and Gross Profit

Cash Flow and Liquidity

Product and Market Dynamics

Strategic Progress and Risks

The Jada System divestiture and the Sebela license for Miudella signal a strategic pivot toward core women's health and biosimilars. However, material weaknesses in internal controls over financial reporting remain un-remediated, stemming from former CEO misconduct related to Nexplanon wholesaler sales. Management has implemented enhanced controls, training, and a new Disclosure Committee charter, but the weaknesses persist as of March 31, 2026. Investors should monitor remediation progress and potential financial statement risks.